{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:09:58Z","timestamp":1781921398520,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300047"],"award-info":[{"award-number":["NIHR300047"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300588"],"award-info":[{"award-number":["NIHR300588"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yorkshire Cancer Research","award":["L389SS"],"award-info":[{"award-number":["L389SS"]}]},{"name":"Yorkshire Cancer Research","award":["RA\/2019\/R1\/005"],"award-info":[{"award-number":["RA\/2019\/R1\/005"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Prostate cancer (PCa) is the most common male malignancy in the western world. Many men (40%) are diagnosed with localised low or intermediate-risk PCa, which is suitable for active surveillance (AS). AS affords careful monitoring to identify changes in otherwise non-life-threatening cancers. While AS reduces overtreatment (and quality of life impact), long-term compliance can be poor, with many men undergoing radical treatment after starting AS.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer (FINESSE) is a prospective, open-label, two-arm, phase 3 trial, in which men with low or intermediate PCa are randomised (1:1) to receive AS with or without finasteride (5 mg once a day for 2 years). Randomisation is stratified by age and PCa risk. AS includes regular prostate-specific antigen testing, MRI scans and the offer of repeat biopsy (at 3 years, or if imaging suggests progression). Additional MRI scans and\/or biopsies will be performed for biochemical or clinical indications. We aim to recruit 550 men (aged 50 to 75 years) from up to eight sites. Active outpatient follow-up will be for 3\u20135 years (depending on date recruited), followed by passive registry-based follow-up for up to 10 years. Primary outcome is adherence to AS. Secondary outcomes include rates and type of disease progression, treatments received (for PCa and benign prostatic enlargement), overall and PCa-specific mortality, an understanding of patients\/professionals views of this approach and health-related quality of life. An external panel of experts blinded to allocation will review all AS cessation and progression events. Trial pathologist\u2019s and radiologist\u2019s, blinded to allocation, will review representative cases. Analysis is Intention to Treat.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study received Health Research Authority and South-Central Oxford Research Ethics Committee (14\/12\/2021: 21\/SC\/0349) and CTA\/MHRA (29\/12\/2021: 21304\/0274\/001\u20130001) approvals. Results will be made available to providers and researchers via publicly accessible scientific journals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" specific-use=\"clinicaltrial \" xlink:href=\"ISRCTN16867955\">ISRCTN16867955<\/jats:ext-link>\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-096431","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T03:43:39Z","timestamp":1739331819000},"page":"e096431","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Protocol for a randomised phase 3 trial evaluating the role of Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer: the FINESSE Study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct16867955","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn16867955","registry":"10.18810\/isrctn"}],"author":[{"given":"Marcus","family":"Cumberbatch","sequence":"first","affiliation":[{"name":"Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"},{"name":"The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"North","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseann","family":"Kealy","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-4470","authenticated-orcid":false,"given":"Samuel","family":"Smith","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kennish","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Bhattrai","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Leeds Teaching Hospital NHS Foundation Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cross","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Chahal","sequence":"additional","affiliation":[{"name":"Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bryant","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, University of Oxford Nuffield, Oxford, UK"},{"name":"Urology, Churchill Hospital, Oxford, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, University of Oxford Nuffield, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohantha","family":"Dooldeniya","sequence":"additional","affiliation":[{"name":"Department of Urology, Mid Yorkshire Teaching NHS Trust, Wakefield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Faulkner","sequence":"additional","affiliation":[{"name":"Metro Charity, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-8744","authenticated-orcid":false,"given":"Peter","family":"Sasieni","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-8828","authenticated-orcid":false,"given":"James","family":"Catto","sequence":"additional","affiliation":[{"name":"Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"},{"name":"Division of Clinical Medicine, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"2025070104271067000_15.2.e096431.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.005"},{"key":"2025070104271067000_15.2.e096431.2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"2025070104271067000_15.2.e096431.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062"},{"key":"2025070104271067000_15.2.e096431.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1192"},{"key":"2025070104271067000_15.2.e096431.5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.juro.2015.11.075","article-title":"Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance","volume":"195","author":"Yamamoto","year":"2016","journal-title":"J Urol"},{"key":"2025070104271067000_15.2.e096431.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6036"},{"key":"2025070104271067000_15.2.e096431.7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in sweden","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025070104271067000_15.2.e096431.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8112"},{"key":"2025070104271067000_15.2.e096431.9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/cncr.24882","article-title":"Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?","volume":"116","author":"van den Bergh","year":"2010","journal-title":"Cancer"},{"key":"2025070104271067000_15.2.e096431.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.004"},{"key":"2025070104271067000_15.2.e096431.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70162-0"},{"key":"2025070104271067000_15.2.e096431.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"2025070104271067000_15.2.e096431.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.007"},{"key":"2025070104271067000_15.2.e096431.14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the g\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"key":"2025070104271067000_15.2.e096431.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.001"},{"key":"2025070104271067000_15.2.e096431.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61619-X"},{"key":"2025070104271067000_15.2.e096431.17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025070104271067000_15.2.e096431.18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"2025070104271067000_15.2.e096431.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.023"},{"key":"2025070104271067000_15.2.e096431.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.04.043"},{"key":"2025070104271067000_15.2.e096431.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4252"},{"key":"2025070104271067000_15.2.e096431.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70388-1"},{"key":"2025070104271067000_15.2.e096431.23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/MOU.0000000000000671","article-title":"Active surveillance for intermediate-risk prostate cancer: yes, but for whom?","volume":"29","author":"Overland","year":"2019","journal-title":"Curr Opin Urol"},{"key":"2025070104271067000_15.2.e096431.24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.euo.2018.08.004","article-title":"Recommendations of active surveillance for intermediate-risk prostate cancer: results from a national survey of radiation oncologists and urologists","volume":"2","author":"Kim","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"2025070104271067000_15.2.e096431.25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.juro.2017.08.088","article-title":"Patients with intermediate risk prostate cancer may be good candidates for active surveillance: con","volume":"198","author":"Tosoian","year":"2017","journal-title":"J Urol"},{"key":"2025070104271067000_15.2.e096431.26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.juro.2017.03.123","article-title":"Intermediate-term outcomes for men with very low\/low and intermediate\/high risk prostate cancer managed by active surveillance","volume":"198","author":"Nyame","year":"2017","journal-title":"J Urol"},{"key":"2025070104271067000_15.2.e096431.27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-096431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:13:10Z","timestamp":1754496790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-096431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-096431"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-096431","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}